艾意凯：2024年范围三排放：制药公司的战略要务报告（英文版）（20页）.pdf

1、SPECIAL REPORTScope 3 Emissions:A Strategic Imperative forPharmaCompanies SPECIAL REPORT1.Key takeaways 32.Introduction 33.What are Scope 3 emissions in pharma,and why do they matter?44.What is the current state of Scope 3 commitments in the pharmaceutical industry?65.What are the key drivers of pha

2、rma companies Scope 3 emissions?116.What are the strategic co-benefits of Scope 3 emissions reduction,and how can companies accomplish them?157.Conclusion 17About L.E.K.ConsultingWere L.E.K.Consulting,a global strategy consultancy working with business leaders to seize competitive advantage and ampl

3、ify growth.Our insights are catalysts that reshape the trajectory of our clients businesses,uncovering opportunities and empowering them to master their moments of truth.Since 1983,our worldwide practice spanning the Americas,Asia Pacific and Europe has guided leaders across all industries from glob

4、al corporations to emerging entrepreneurial businesses and private equity investors.Looking for more?Visit .L.E.K.Consulting is a registered trademark of L.E.K.Consulting LLC.All other products and brands mentioned in this document are properties of their respective owners.2024 L.E.K.Consulting LLCC

5、ontents2 L.E.K.ConsultingSPECIAL REPORTKey takeawaysIntroduction Net-zero emissions initiatives have gained traction in recent years,particularly in the pharmaceutical industry.Pharma has traditionally lagged other industries in emissions commitments,but market pressures from customers(e.g.,health s

6、ystems)and regulators have contributed to shifting emissions targets into focus.Thirteen of the top 20 pharma companies by revenue have committed to net-zero,and among these,over half made their commitments in the past three years(see Figure 3 below).Scope 3 emissions reductions are becoming not onl